Melatonin-Related Sleep Science Sparks Hope For Treating Sleep Disorders

Millions of people worldwide struggle with sleep disorders, compromising their health and quality of life. These conditions often coexist with mental health issues, neuropathic pain and other medical problems. However, a groundbreaking study published in the Journal of Neuroscience offers new hope.

Researchers at McGill University and the University of Padua have made a significant breakthrough in understanding melatonin’s role in treating sleep disorders and related mental health conditions. Their findings reveal the crucial function of the melatonin MT1 receptor in regulating sleep, particularly during the rapid eye movement (REM) stage.

What is REM sleep?

Considered as the brain’s ‘restore-and-recharge’ phase, this is the time when people dream and when memories get stored. REM sleep is associated with essential brain functions.

The brain receptor (melatonin MT1) further broadens the understanding of sleep mechanisms, thereby providing the potential of promising clinical results.

“By understanding the MT1 receptor, we might be on the brink of creating new and better treatments for sleep disorders and related conditions like Parkinson’s and dementia,” Earth.com reported.

Understanding the sleep science

In their research, the scientists have majorly focused on a critical region of the brain, called the ‘Locus Coeruleus’ or the ‘blue spot’. Under this, the MT1 receptor interacts with a specific neuron type that altogether produces noradrenaline, that works both as a neurotransmitter and a hormone. It is responsible for keeping us awake and alert.

During REM sleep, this region in the brain becomes ‘light/inactive’, thereby allowing people to take entry into the dream state, reports said.

In the entire process, the Melatonin MT1 brain receptor has a key role to play in switching the brain from the alert to dream stage. Located in the blue spot region, this receptor is tasked with ‘switching off’ the noradrenaline.

To check its role in REM sleep, the team of scientists introduced a new drug (UCM871) to the MT1 melatonin receptor in rats, which ultimately extended the REM sleep duration.

Gabriella Gobbi, a professor of psychiatry at McGill University and the study’s principal investigator, said, “This discovery not only advances our understanding of sleep mechanisms but also holds significant clinical potential”.

However, inadequate REM sleep can lead to multiple issues including the problems with memory, emotional balance, focus and overall mental health.